mRNA specialist Moderna (Nasdaq: MRNA) has reported a decline in revenues for the second quarter of 2024, taking in $241 million, down from $344 million in the same period last year.
The company's net loss was $1.3 billion, equating to a loss per share of $3.33, compared to a net loss of $1.4 billion and a loss per share of $3.62 in the second quarter of 2023.
The decline in revenue was primarily driven by reduced sales of Spikevax, Moderna's COVID-19 vaccine, reflecting the anticipated shift to a seasonal market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze